Evidence map›Paper›PMID 40484944›Full record

ArticleCancer cell international2025

Marine natural product Methyl mycophenolate inhibits gastric cancer growth through regulating p53 and the downstream pathways.

Xiaofang Liu, Ning Xu, Jie Wang, Kaining Chen, Huiwen Ke, Yufen Xu, Dianying Feng, Lishi Xiao, Xiangqi Meng, Shi Chen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaofang Liu *Department of Laboratory Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China.
Ning Xu *Department of Laboratory Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China.
Jie Wang *Department of Radiation Oncology, Dalian Municipal Central Hospital, Dalian, 116033, China.
Kaining ChenDepartment of Clinical Biological Resource Bank, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510620, China.
Huiwen KeDepartment of Laboratory Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China.
Yufen XuDepartment of Clinical Biological Resource Bank, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510620, China.
Dianying FengGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.
Lishi XiaoGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.
Xiangqi MengGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China. mengxq3@mail.sysu.edu.cn.
Shi ChenDepartment of General Surgery, Department of Gastrointestinal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, 510655, Guangzhou, China. chensh47@mail.sysu.edu.cn.
Hongyan YuDepartment of Clinical Biological Resource Bank, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510620, China. annayu@gwcmc.org.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2023A1515030261National Natural Science Foundation of China 82102973National Natural Science Foundation of China 82273133the Guangzhou Science and Technology Program Project 2025A03J4388
6 · The paper itself

Abstract

backgroundGastric cancer (GC) is one of the most prevalent cancers and the fifth leading cause of cancer-related deaths globally. Methyl mycophenolate (MMP), a methyl ester derivative of mycophenolic acid, is derived from the marine fungus Phaeosphaeria spartinae, yet its role in GC remains unexplored. PURPOSE: This study aims to investigate the therapeutic potential of MMP in GC and elucidate its underlying mechanisms.

methodsWe screened marine compounds for their inhibitory activity against GC cells using cell viability, colony formation assays, cell cycle analysis, and apoptosis detection. RNA sequencing and KEGG enrichment analysis identified key downstream pathways activated by MMP. Western blotting, qRT-PCR, and immunohistochemistry confirmed changes in the p53 signaling pathway. Protein stability was assessed through turnover and ubiquitination assays, while Co-IP verified the effect of MMP on p53 binding to MDM2. An in vivo tumorigenesis study evaluated MMP's efficacy and safety in mice.

resultsMMP significantly inhibited GC cell proliferation and colony formation, induced apoptosis through the caspase pathway, and caused cell cycle G1 arrest by downregulating CDK4, CDK2 and upregulating p27. Mechanistically, MMP increased p53 protein levels and activated downstream targets (p21, PUMA, GADD45A) in a dose-dependent manner. It enhanced p53 stability by reducing ubiquitination. MMP injection in mice significantly inhibited tumor growth in a subcutaneous xenograft model.

conclusionMMP displays anti-GC activity by inducing apoptosis and cell cycle arrest via the p53 pathway. Our findings suggest MMP's potential as a therapeutic agent for GC intervention.

Indexed as

Gastric cancerMethyl mycophenolateNatural marine compoundsp53Ubiquitination

Identifiers

PMID40484944
PMCPMC12147254

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.